FDA-approved drugs go through FDAs rigorous review for safety, effectiveness, and quality as part of the premarket approval process
The program provides a year of free Noom or substantial medication discounts to anyone who regains the weight within 18 months following a 12-month course of Noom GLP-1Rx, including Nooms taper protocol
This public-to-private handoff is a textbook example of how healthcare innovation often works
Global GLP-1 innovation is being driven by major pharmaceutical leaders including Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Boehringer Ingelheim International GmbH, Amgen Inc., Biocon, and Teva Pharmaceuticals, who continue to expand treatment options across diabetes, obesity, and metabolic disorders